1. Temporary policy on repackaging or combining propofol drug products during the COVID-19 public health emergency Publication: [Silver Spring, MD] : Center for Drug Evaluation and Research, Office of Pharmaceutical Quality and Office of Compliance, April 2020 Subject(s): Drug Packaging -- methodsPropofol -- supply & distributionCOVID-19Drug LabelingPharmaciesUnited StatesUnited States. Department of Health and Human Services.United States. Food and Drug Administration.
2. Temporary policy for compounding of certain drugs for hospitalized patients by pharmacy compounders not registered as outsourcing facilities during the COVID-19 public health emergency (revised) Publication: [Silver Spring, MD] : Center for Drug Evaluation and Research, Office of Compliance May 21, 2020 Subject(s): Drug Compounding -- methodsHospitalizationOutsourced ServicesPharmaciesCOVID-19United StatesUnited States. Department of Health and Human Services.United States. Food and Drug Administration.
